Cancer Education and Research Institute
Worldwide Access to High-Quality Care, Research, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2022
      • CERI Press Releases 2021
      • Press Releases 2020
      • Press Releases 2019
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • For Patients
    • CERI Personalized Patient Program™
    • All about cancer
    • Cancer Education
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us

CERI Cancer Quiz Day Earth Day Special

4/21/2021

1 Comment

 
    We won't spam you; we won't share your information.
Submit
1 Comment

FDA approved first immunotherapy for initial treatment of gastric cancer

4/16/2021

0 Comments

 
Picture
Today, on April 16, 2021, the Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with certain chemotherapy for patients with for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer and esophageal adenocarcinoma.
This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.
  • How does Opdivo (nivolumab) work? Opdivo is a monoclonal antibody that inhibits tumor growth by enhancing T-cell function.
  • How many patients were evaluated for this study? 1,581
  • Median overall survival (OS) for the pembrolizumab + chemotherapy arm: 13.8 months
  • Median overall survival (OS) for the chemotherapy arm: 11.6 months
  • What were the most common adverse reactions? The most common side effects of Opdivo in combination with chemotherapy include:
    • peripheral neuropathy (damage to the nerves outside of the brain and spinal cord),
    • nausea,
    • fatigue,
    • diarrhea,
    • vomiting,
    • decreased appetite,
    • abdominal pain,
    • constipation,
    • musculoskeletal pain.
  • Opdivo can cause serious conditions known as immune-mediated side effects, including:
    • inflammation of healthy organs such as the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (endocrinopathies) and kidneys (nephritis).
  • Patients should tell their healthcare providers if they have immune system problems, lung or breathing problems, liver problems, have had an organ transplant, or are pregnant or plan to become pregnant before starting treatment.

Reference:
  • https://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-initial-treatment-gastric-cancer?s=03 (accessed April 16, 2021).
0 Comments

Cancer Quiz Day

4/14/2021

0 Comments

 
    We won't spam you; we won't share your information.
Submit
PS: You can find the answer here.
0 Comments

FDA approved pembrolizumab for esophageal or GEJ carcinoma

4/13/2021

0 Comments

 
Picture
On March 22, 2021, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.
  • How many patients were evaluated for this study? 749
  • What is the study ID? KEYNOTE-590 (NCT03189719)
  • How were patients randomized? (1:1) to pembrolizumab in combination with cisplatin and fluorouracil or placebo with cisplatin and fluorouracil, until unacceptable toxicity or disease progression.
  • What were the results of the study? Statistically significant improvement in overall survival (OS) and progression-free survival (PFS) for patients randomized to pembrolizumab with chemotherapy.
  • Median OS for the pembrolizumab arm: 12.4 months (95% CI: 10.5, 14.0) 
  • Median OS for the chemotherapy arm: 9.8 months (95% CI: 8.8, 10.8) (HR 0.73; 95% CI: 0.62, 0.86; p<0.0001).
  • Median PFS for the pembrolizumab arm: 6.3 months (95% CI: 6.2, 6.9)
  • Median PFS for the chemotherapy arm: 5.8 months (95% CI: 5.0, 6.0) (HR 0.65; 95% CI: 0.55, 0.76; p<0.0001).
  • What were the most common adverse reactions? In ≥20% of patients who received the pembrolizumab combination were nausea, constipation, diarrhea, vomiting, stomatitis, fatigue/asthenia, decreased appetite, and weight loss.
  • What is the recommended pembrolizumab dose for esophageal cancer? 200 mg every 3 weeks or 400 mg every 6 weeks.
Reference:
  • FDA approves pembrolizumab for esophageal or GEJ carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma (accessed April 13, 2021)
0 Comments

Wednesday Cancer Quiz Day

4/7/2021

0 Comments

 
Picture
This is our long-time game we've created, the CERI Cancer Quiz Game™!
Test your cancer knowledge with CERI - take today's quiz, share with you friends!
Every Wednesday!

0 Comments

Cancer Quiz Day

4/7/2021

0 Comments

 
    We won't spam you, we won't share your information.
Submit
You can find the correct answer in two of our videos on our Youtube channel:
  • https://www.youtube.com/watch?v=ZGvw2iw6nS8
  • https://www.youtube.com/watch?v=Fq-ugrt_H-E

COME BACK EVERY WEDNESDAY FOR OUR 'QUESTION OF THE DAY' QUIZ!

0 Comments

Schwann Cells Promote Cancer Cell Invasion

4/6/2021

0 Comments

 
By Ayguen Sahin, MSc, PhD - Cancer Education and Research Institute
Picture
In some cancers, cancer cells can invade in along nerves causing an aggressive perineural invasion (PNI, the invasion of cancer to the space surrounding a nerve), which leads to pain and paralysis, and reduced survival.

A study led by Deborde and colleagues showed that cancer cells exploit normal Schwann cell nerve repair programs to promote perineural invasion.  This research study observed these results in:
  • pancreatic adenocarcinoma
  • thyroid cancer
  • salivary duct carcinoma

Schwann cells are a type of glial cells, which surrounds neurons and play an essential role in the fuction and survival of the neurons.

Cancer cells formed protrusions and migration toward Schwann cells through a protein called NCAM1 (Neural Adhesion Molecule 1), which is correlated with the presence of perineural invasion. 

Perineural invasion (PNI) is also often seen in:
  • head and neck cancer
  • prostate cancer
  • colorectal cancer


Resources:
  1. Deborde S, Omelchenko T, Lyubchik A, Zhou Y, He S, McNamara WF, et al. Schwann cells induce cancecr cell dispersion and invasion. J Clin Invest 2016; 126:1538-54. 
  2. Cancer Discovery, May 2016, 473.
  3. Ström P, et al. Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. J Clin Pathol 2020 Oct;73(10):630-635.
  4. Schmitd  LB, et al. Perineural Invasion in Head and Neck Cancer. J Dent Res 2018 Jul;97(7):742-750.
  5. Knijn N, et al. Perineural Invasion is a Strong Prognostic Factor in Colorectal Cancer: A Systematic Review. Am J Surg Pathol. 2016 Jan;40(1):103-12.
  6. NCAM1 neural cell adhesion molecule 1 [Homo sapiens (human)], https://www.ncbi.nlm.nih.gov/gene/4684 (accessed April 6, 2021)
  7. Schwann Cells, Biology Dictionary. https://biologydictionary.net/schwann-cells (accessed April 6, 2021)
0 Comments

    Archives

    March 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    May 2020
    April 2020
    March 2020
    September 2019
    June 2019
    May 2019
    October 2018
    February 2017
    January 2017
    December 2016
    November 2016
    September 2016
    June 2016
    May 2016
    April 2016
    March 2016
    January 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013

    Categories

    All
    Cancer News
    Cancer News
    Cancer Research Simplified News
    Crs News
    Crs News
    Holidays
    Quotes

Yes, I'd like to help CERI continue saving lives!

Make a Monthly Contribution

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2023 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®